Based on these positive results, the clinical efficacy, safety, and pharmacology of ION363 (jacifusen) are being evaluated in Phase III clinical trials in ALS patients with FUS mutations (FUSION; NCT04768972). Here, FUS is linked to amyotrophic lateral sclerosis.